UNAIDS Treatment 2.0 based on made-in-B.C. “treatment as prevention” strategy A radical new approach to HIV treatment, dubbed “Treatment 2.0,” aims to dramatically increase testing andtreatment for HIV using the best available diagnostic tools and drugs, announced Michel Sidibé, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS), at the XVIII International AIDS […]
June, 2010 – The Pharmacovigilance Program at the BC Centre for Excellence in HIV/AIDS has received four reports of suspected drug interaction between ritonavir and triamcinolone acetonide intra-articular injection leading to symptoms of corticosteroid excess (Cushingoid features) and adrenal suppression. The affected patients were HIV-infected adults whose antiretroviral therapy included a protease inhibitor boosted with
SAFETY ALERT: RITONAVIR AND INTRA-ARTICULAR TRIMCINOLONE ACETONIDE INJECTION Read More »
NIDA director a strong supporter of the BC-CfE’s Seek and Treat strategy to fight HIV At a special ceremony on May 31, 2010, Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health, was awarded an honorary degree of Doctor of Science by the University of British
UNAIDS chief demands Harper put universal access on G8 agenda during UBC forum UNAIDS chief Michel Sidibé told a blue-ribbon panel of world health leaders brought together by the BC Centre for Excellence in HIV/AIDS (BC-CfE) that Prime Minister Stephen Harper must put universal access to HIV therapies back on the Group of Eight (G8)
NIDA invests $50 million to evaluate made-in-BC strategy for control of HIV/AIDS The US National Institute on Drug Abuse (NIDA) intends to fund research worth up to US$50 million over five years to evaluate the “seek-and-treat” strategy originally developed at the BC Centre for Excellence in HIV/AIDS (BC-CfE). NIDA has issued a Request for Applications
July, 2009 – The Pharmacovigilance Initiative at the BC Centre for Excellence in HIV/AIDS received a report of an HLA-B*5701 positive patient who had tolerated long term abacavir therapy, discontinued antiretroviral drugs for several months, then developed a diffuse rash, respiratory distress and fever shortly after re-initiating an abacavir-containing regimen. The symptoms and rapid onset were
SAFETY WARNING: ABACAVIR USE IN HLA-B*5701 POSITIVE PATIENTS AND UNTESTED PATIENTS Read More »
Aboriginal street youth more likely to be HIV-positive In Canada, there are upwards of 150,000 homeless and street-involved youth, and they are far more vulnerable to HIV and other sexually transmitted infections. In fact, infection rates for diseases such as chlamydia and gonorrhea are 10 times that of the general adolescent population in the country.
